| Item Type | Name |
|
Academic Article
|
Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma.
|
|
Academic Article
|
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
|
|
Academic Article
|
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
|
|
Concept
|
Lymphoma, T-Cell
|
|
Concept
|
Lymphoma, T-Cell, Peripheral
|
|
Concept
|
Lymphoma, B-Cell
|
|
Concept
|
Lymphoma, Mantle-Cell
|
|
Concept
|
Lymphoma, Large-Cell, Anaplastic
|
|
Concept
|
Lymphoma, B-Cell, Marginal Zone
|
|
Academic Article
|
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
|
|
Academic Article
|
TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.
|
|
Academic Article
|
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
|
|
Academic Article
|
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
|
|
Academic Article
|
Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations.
|
|
Academic Article
|
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
|
|
Academic Article
|
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.
|
|
Academic Article
|
Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: newer therapies needed.
|
|
Academic Article
|
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
|
|
Academic Article
|
Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
|
|
Academic Article
|
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
|
|
Academic Article
|
Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation.
|
|
Academic Article
|
Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series.
|
|
Academic Article
|
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
|
|
Academic Article
|
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
|
|
Academic Article
|
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
|
|
Academic Article
|
Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD.
|
|
Academic Article
|
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
|
|
Academic Article
|
Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
|
|
Academic Article
|
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
|
|
Academic Article
|
B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
|
|
Academic Article
|
Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma.
|
|
Academic Article
|
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.
|
|
Academic Article
|
Recent advances in de novo CD5+ diffuse large B cell lymphoma.
|
|
Academic Article
|
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma.
|
|
Academic Article
|
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
|
|
Academic Article
|
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
|
|
Academic Article
|
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
Mantle cell lymphoma with a rare involvement of the testicle.
|
|
Academic Article
|
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
|
|
Academic Article
|
Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification.
|
|
Academic Article
|
Marginal zone lymphomas: factors that affect the final outcome.
|
|
Academic Article
|
Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
|
|
Academic Article
|
Bortezomib-resistant nuclear factor ?B expression in stem-like cells in mantle cell lymphoma.
|
|
Academic Article
|
Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
|
|
Academic Article
|
Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases.
|
|
Academic Article
|
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
|
|
Academic Article
|
Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production.
|
|
Academic Article
|
The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.
|
|
Academic Article
|
Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.
|
|
Academic Article
|
Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et?al.
|
|
Academic Article
|
Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma.
|
|
Academic Article
|
Prospective isolation of clonogenic mantle cell lymphoma-initiating cells.
|
|
Academic Article
|
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
|
|
Academic Article
|
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.
|
|
Academic Article
|
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.
|
|
Academic Article
|
Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease.
|
|
Academic Article
|
Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
|
|
Academic Article
|
Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.
|
|
Academic Article
|
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
|
|
Academic Article
|
A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma.
|
|
Academic Article
|
Targeting Wnt pathway in mantle cell lymphoma-initiating cells.
|
|
Academic Article
|
Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.
|
|
Academic Article
|
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
|
|
Academic Article
|
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.
|
|
Academic Article
|
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
|
|
Academic Article
|
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
|
|
Academic Article
|
A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma
|
|
Academic Article
|
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma
|
|
Academic Article
|
Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma
|
|
Academic Article
|
Diffuse large b-cell lymphoma version 1.2016
|
|
Academic Article
|
Targeting Wnt pathway in mantle cell lymphoma-initiating cells
|
|
Academic Article
|
Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma
|
|
Academic Article
|
Comparison of survival in patients with t cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease
|
|
Academic Article
|
Randomized, double-blind, phase 3 trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-Cell lymphoma
|
|
Academic Article
|
Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma
|
|
Academic Article
|
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma
|
|
Academic Article
|
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma
|
|
Academic Article
|
Diffuse large B-Cell lymphoma
|
|
Academic Article
|
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma
|
|
Academic Article
|
A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
|
|
Academic Article
|
Diffuse Large B-Cell Lymphoma Version 1.2016.
|
|
Academic Article
|
Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
|
|
Academic Article
|
Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
|
|
Academic Article
|
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.
|
|
Academic Article
|
Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum ?2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.
|
|
Academic Article
|
Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma.
|
|
Academic Article
|
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.
|
|
Academic Article
|
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
|
|
Academic Article
|
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.
|
|
Academic Article
|
Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma.
|
|
Academic Article
|
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.
|
|
Academic Article
|
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions.
|
|
Academic Article
|
Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.
|
|
Academic Article
|
The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.
|
|
Academic Article
|
Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure.
|
|
Academic Article
|
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.
|
|
Academic Article
|
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
|
|
Academic Article
|
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
|
|
Academic Article
|
Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma.
|
|
Academic Article
|
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
|
|
Academic Article
|
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
|
|
Academic Article
|
Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy.
|
|
Academic Article
|
Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy.
|
|
Academic Article
|
Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue.
|
|
Academic Article
|
Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma.
|
|
Academic Article
|
Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.
|
|
Academic Article
|
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.
|
|
Academic Article
|
A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.
|
|
Academic Article
|
Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection.
|
|
Academic Article
|
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
|
|
Academic Article
|
De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.
|
|
Academic Article
|
Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.
|
|
Academic Article
|
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
|
|
Academic Article
|
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
|
|
Academic Article
|
Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma.
|
|
Academic Article
|
Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.
|
|
Academic Article
|
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma.
|
|
Academic Article
|
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.
|
|
Academic Article
|
The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.
|
|
Academic Article
|
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.
|
|
Academic Article
|
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
|
|
Academic Article
|
18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study.
|
|
Academic Article
|
A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
|
|
Academic Article
|
NCCN Guidelines? Insights: B-Cell Lymphomas, Version 5.2021.
|
|
Academic Article
|
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
|
|
Academic Article
|
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
|
|
Academic Article
|
Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma.
|
|
Academic Article
|
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
|
|
Academic Article
|
Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.
|
|
Academic Article
|
Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
|
|
Academic Article
|
A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma.
|
|
Academic Article
|
Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant.
|
|
Academic Article
|
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.
|
|
Academic Article
|
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma.
|
|
Academic Article
|
Prolonged cytopenia following CD19 CAR T?cell therapy is linked with bone marrow infiltration of clonally expanded IFN?-expressing CD8 T?cells.
|
|
Academic Article
|
NCCN Guidelines? Insights: B-Cell Lymphomas, Version 6.2023.
|
|
Academic Article
|
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
|
|
Academic Article
|
Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
|
|
Academic Article
|
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
|